Last reviewed · How we verify
NCT05268692
Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP
Phase 2, PHASE3 trial testing GS in Pancreatic Adenocarcinoma in 500 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | Kochi University |
|---|---|
| Phase | Phase 2, PHASE3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 500 |
| Start date | 1 January 2019 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2030 |
| Sites | 1 location across Japan |
Drugs / interventions tested
Conditions studied
- Pancreatic Adenocarcinoma — all drugs for Pancreatic Adenocarcinoma →
Sponsor
Kochi University
Who can join
Adults 18 to 85, any sex, with Pancreatic Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The effect of neoadjuvant chemotherapy for pancreatic cancer was gradually established. However it has been not clarified which regimen of neoadjuvant treatment for pancreatic cancer is the best.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05268692
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of GS
Trials testing the same drug.
- NCT03869294 — GS Regimen as the First-line Chemotherapy in Chinese Advanced PC Patients · completed
Other recruiting trials for Pancreatic Adenocarcinoma
Currently open trials in the same condition.
- NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
- NCT07488676 — A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07493421 — To Evaluate the Feasibility and Safety of Combining Surgery (Pancreatectomy and Cytoreduction) With HIPEC for Treating P · NA · recruiting
- NCT06896188 — 9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLE · Phase 1 · recruiting
- NCT07090499 — A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors · Phase 1 · recruiting
Other Kochi University trials
Trials by the same sponsor.
- NCT06555510 — Preoperative Edema is a Significant Risk Factor for Post-hepatectomy Complications · completed
- NCT05257434 — Postoperative Outcomes in Patients With Hepato-biliary-pancreatic Cancer According to inBody Test · recruiting
- NCT05257226 — Both Short- and Long-term Outcome Differences According to Patient Frailty · recruiting
- NCT06809374 — Investigation of the Optimal Duration of Neoadjuvant Therapy for Resectable Pancreatic Cancer · completed
- NCT06921252 — Does Recurrent Pancreatic Cancer Really Have Similar Outcome Compared With Primary Metastatic Pancreatic Cancer? · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05268692 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kochi University
- Last refreshed: 7 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05268692.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing